Search

There are multiple disease-modifying immunotherapies showing the potential of preventing or delaying the progression of type 1 diabetes (T1D). We designed and performed this systematic review and meta-analysis to gain an overview of what a role immunotherapy plays in the treatment of T1D. We searched PubMed, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to December 2023. We included clinical trials of immunotherapy conducted in patients with T1D that reported the incidence of hypoglycemia or changes from baseline in at least one of following outcomes: 2 h and 4 h mixed-meal-stimulated C-peptide area under the curve (AUC), fasting C-peptide, daily insulin dosage, glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG). The results were computed as the weighted mean differences (WMDs) or odds ratios (ORs) and 95% confidence intervals (CIs) in random-effect model. In all, 34 clinical trials were included. When compared with control groups, 2 h C-peptide AUC was marginally higher in patient treated with nonantigen-based immunotherapies (WMD, 0.04nmol/L, 95% CI, 0.00–0.09 nmol/L, P=0.05), which was mainly driven by the effects of T cell-targeted therapy. A greater preservation in 4 h C-peptide AUC was observed in patients with nonantigen-based immunotherapies (WMD, 0.10nmol/L, 95% CI, 0.04–0.16 nmol/L, P=0.0007), which was mainly driven by the effects of tumor necrosis factor α (TNF-α) inhibitor and T cell-targeted therapy. After excluding small-sample trials, less daily insulin dosage was observed in patient treated with nonantigen-based immunotherapies when compared with control groups (WMD, −0.07units/kg/day, 95% CI, −0.11 to −0.03units/kg/day, P=0.0004). The use of antigen-based immunotherapies was also associated with a lower daily insulin dosage versus control groups (WMD, −0.11units/kg/day, 95% CI, −0.23 to −0.00units/kg/day, P=0.05). However, changes of HbA1c or FPG were comparable between nonantigen-based immunotherapies or antigen-based immunotherapies and control groups. The risk of hypoglycemia was not increased in patients treated with nonantigen-based immunotherapies or patients treated with antigen-based immunotherapies when compared with control groups. In conclusion, nonantigen-based immunotherapies were associated with a preservation of 2 h and 4 h C-peptide AUC in patients with T1D when compared with the controls, which was mainly driven by the effects of TNF-a inhibitor and T cell-targeted therapy. Both nonantigen-based immunotherapies and antigen-based immunotherapies tended to reduce the daily insulin dosage in patients with T1D when compared with the controls. However, they did not contribute to a substantial improvement in HbA1c or FPG. Both nonantigen-based immunotherapies and antigen-based immunotherapies were well tolerated with not increased risk of hypoglycemia in patients with T1D. [Display omitted] • Immunotherapies were associated with the preservation of 2 h and 4 h C-peptide AUC in patients with T1D. • Immunotherapies tended to reduce the daily insulin dosage in patients with T1D. • Immunotherapies did not increase the risk of hypoglycemia in patients with T1D. • TNF-a inhibitor and T cell-targeted immunotherapy might be promising game changers to delay the development of T1D. [ABSTRACT FROM AUTHOR]

SrSn(OH) 6 (SSOH) possesses a high oxidation potential in the valence band (VB), which is suitable for photocatalytic oxidation removal of pollutants. However, the electrons in the VB of these catalysts are difficult to transition to the conduction band (CB) under visible light, which makes it difficult to utilize sunlight effectively. In this work, Ag/Ag 2 O is loaded on the surface of SSOH nanowires, which stimulates the interfacial charge-transfer transition on SSOH. Compared with pure-phase SSOH, the NO abatement ratio of Ag/Ag 2 O-SSOH under visible light irradiation is increased to 45.10%. The e− in the VB of Ag 2 O are excited into the CB under visible light, and are further transferred to the Ag to react with O 2 to produce superoxide radicals. The photo-excited e− in the VB of SSOH enter into the VB of Ag 2 O through interfacial charge-transfer transition to recombine with the photo-generated holes in the VB of Ag 2 O, thereby leaving photo-generated holes in the VB of SSOH. The holes in the VB of SSOH have sufficient oxidizing ability to oxidize the adsorbed hydroxyl groups into hydroxyl radicals. This work provides a new perspective for photocatalytic removal of pollutants by wide band gap photocatalyst under visible light. [Display omitted] • Ag/Ag 2 O cocatalyst/SrSn(OH)6 nanowires are firstly fabricated. • The Ag/Ag 2 O cocatalyst/SrSn(OH) 6 showed high visible light photocatalytic activity. • The mechanism of photocatalytic NO oxidation is revealed using in situ DRIFTS. • The enhanced photocatalysis is ascribed to the interfacial charge-transfer transition. • The detailed process of the interfacial charge-transfer transition is revealed. [ABSTRACT FROM AUTHOR]

• The use of bDMARDs may confer reduced risk of new-onset diabetes in patients with systemic inflammatory conditions, especially RA. • New-onset diabetes was less frequent in patients with TNF-a inhibitor and abatacept treatment. • TNF-a mediated inflammatory response and dysregulated T cell activation might get involved in the development of diabetes. Whether the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) would influence the risk of new-onset diabetes remains uncertain. Therefore, we performed a systematic review and meta-analysis to evaluate the association between the use of bDMARDs and the incidence of diabetes in patients with systemic inflammatory conditions. Pubmed, Medline, Embase and the Cochrane Central Register of Controlled Trials were searched for studies published from January 2000 to March 2020. Studies conducted in systemic inflammatory conditions with reports of the incidence of diabetes in subjects treated with bDMARDs were included. With 22 randomized controlled trials and 3 cohort studies included, the overall result indicated that compared with non-bDMARD treatment, the use of bDMARDs was significantly associated with decreased incidence of diabetes in patients with systemic inflammatory conditions (RR = 0.56, 95 % CI, 0.43 to 0.74, P < 0.001, I2 = 69 %), especially in patients with in rheumatoid arthritis (RR = 0.54, 95 % CI, 0.38 to 0.76, P = 0.0005, I2 = 26). Reduced risk of new-onset diabetes was observed in studies with follow-up more than 1 year (RR = 0.73, 95 % CI, 0.54 to 0.99, P = 0.04, I2 = 88). New-onset diabetes was less frequent in patients with TNF-α inhibitor treatment (RR = 0.54, 95 % CI, 0.48 to 0.60, P < 0.001, I2 = 42 %) and abatacept treatment (RR = 0.44, 95 % CI, 0.34 to 0.58, P < 0.001, I2 = 3 %), which might be associated with the inhibition of TNF-α mediated inflammatory responses and dysregulated T cell activation and immune responses respectively. Further investigations are required to validate the glucose metabolism protective effect of bDMARDs and clarify the underlying mechanisms of the crosstalk between bDMARDs and diabetes. [ABSTRACT FROM AUTHOR]